SC83288 is a clinical development candidate for the treatment of severe malaria

Severe malaria is a life-threatening infection with limited treatment options. Here, using a medicinal chemistry approach starting from amicarbalide, Pegoraroet al. identify a compound that, when delivered intravenously, can cure Plasmodium falciparuminfection in a humanized mouse model.

Guardado en:

Detalles Bibliográficos
Autores principales:	Stefano Pegoraro, Maëlle Duffey, Thomas D Otto, Yulin Wang, Roman Rösemann, Roland Baumgartner, Stefanie K Fehler, Leonardo Lucantoni, Vicky M Avery, Alicia Moreno-Sabater, Dominique Mazier, Henri J Vial, Stefan Strobl, Cecilia P Sanchez, Michael Lanzer
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/31209cc459aa4f289ae53a99dad149ad
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:31209cc459aa4f289ae53a99dad149ad
record_format	dspace
spelling	oai:doaj.org-article:31209cc459aa4f289ae53a99dad149ad2021-12-02T14:42:21ZSC83288 is a clinical development candidate for the treatment of severe malaria10.1038/ncomms141932041-1723https://doaj.org/article/31209cc459aa4f289ae53a99dad149ad2017-01-01T00:00:00Zhttps://doi.org/10.1038/ncomms14193https://doaj.org/toc/2041-1723Severe malaria is a life-threatening infection with limited treatment options. Here, using a medicinal chemistry approach starting from amicarbalide, Pegoraroet al. identify a compound that, when delivered intravenously, can cure Plasmodium falciparuminfection in a humanized mouse model.Stefano PegoraroMaëlle DuffeyThomas D OttoYulin WangRoman RösemannRoland BaumgartnerStefanie K FehlerLeonardo LucantoniVicky M AveryAlicia Moreno-SabaterDominique MazierHenri J VialStefan StroblCecilia P SanchezMichael LanzerNature PortfolioarticleScienceQENNature Communications, Vol 8, Iss 1, Pp 1-17 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Stefano Pegoraro Maëlle Duffey Thomas D Otto Yulin Wang Roman Rösemann Roland Baumgartner Stefanie K Fehler Leonardo Lucantoni Vicky M Avery Alicia Moreno-Sabater Dominique Mazier Henri J Vial Stefan Strobl Cecilia P Sanchez Michael Lanzer SC83288 is a clinical development candidate for the treatment of severe malaria
description	Severe malaria is a life-threatening infection with limited treatment options. Here, using a medicinal chemistry approach starting from amicarbalide, Pegoraroet al. identify a compound that, when delivered intravenously, can cure Plasmodium falciparuminfection in a humanized mouse model.
format	article
author	Stefano Pegoraro Maëlle Duffey Thomas D Otto Yulin Wang Roman Rösemann Roland Baumgartner Stefanie K Fehler Leonardo Lucantoni Vicky M Avery Alicia Moreno-Sabater Dominique Mazier Henri J Vial Stefan Strobl Cecilia P Sanchez Michael Lanzer
author_facet	Stefano Pegoraro Maëlle Duffey Thomas D Otto Yulin Wang Roman Rösemann Roland Baumgartner Stefanie K Fehler Leonardo Lucantoni Vicky M Avery Alicia Moreno-Sabater Dominique Mazier Henri J Vial Stefan Strobl Cecilia P Sanchez Michael Lanzer
author_sort	Stefano Pegoraro
title	SC83288 is a clinical development candidate for the treatment of severe malaria
title_short	SC83288 is a clinical development candidate for the treatment of severe malaria
title_full	SC83288 is a clinical development candidate for the treatment of severe malaria
title_fullStr	SC83288 is a clinical development candidate for the treatment of severe malaria
title_full_unstemmed	SC83288 is a clinical development candidate for the treatment of severe malaria
title_sort	sc83288 is a clinical development candidate for the treatment of severe malaria
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/31209cc459aa4f289ae53a99dad149ad
work_keys_str_mv	AT stefanopegoraro sc83288isaclinicaldevelopmentcandidateforthetreatmentofseveremalaria AT maelleduffey sc83288isaclinicaldevelopmentcandidateforthetreatmentofseveremalaria AT thomasdotto sc83288isaclinicaldevelopmentcandidateforthetreatmentofseveremalaria AT yulinwang sc83288isaclinicaldevelopmentcandidateforthetreatmentofseveremalaria AT romanrosemann sc83288isaclinicaldevelopmentcandidateforthetreatmentofseveremalaria AT rolandbaumgartner sc83288isaclinicaldevelopmentcandidateforthetreatmentofseveremalaria AT stefaniekfehler sc83288isaclinicaldevelopmentcandidateforthetreatmentofseveremalaria AT leonardolucantoni sc83288isaclinicaldevelopmentcandidateforthetreatmentofseveremalaria AT vickymavery sc83288isaclinicaldevelopmentcandidateforthetreatmentofseveremalaria AT aliciamorenosabater sc83288isaclinicaldevelopmentcandidateforthetreatmentofseveremalaria AT dominiquemazier sc83288isaclinicaldevelopmentcandidateforthetreatmentofseveremalaria AT henrijvial sc83288isaclinicaldevelopmentcandidateforthetreatmentofseveremalaria AT stefanstrobl sc83288isaclinicaldevelopmentcandidateforthetreatmentofseveremalaria AT ceciliapsanchez sc83288isaclinicaldevelopmentcandidateforthetreatmentofseveremalaria AT michaellanzer sc83288isaclinicaldevelopmentcandidateforthetreatmentofseveremalaria
_version_	1718389680850862080

SC83288 is a clinical development candidate for the treatment of severe malaria

Ejemplares similares